Page last updated: 2024-11-07

4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol : A member of the class of nitrosamines that is butan-1-ol substituted by a pyridin-3-yl group at position 1 and by a methyl(nitroso)amino group at position 4. It is a major metabolite of nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which is a carcinogen found in tobacco and responsible for inducing lung cancer in smokers. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID104856
CHEBI ID82569
SCHEMBL ID452534
MeSH IDM0261327

Synonyms (38)

Synonym
4-[methyl(nitroso)amino]-1-pyridin-3-ylbutan-1-ol
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
76014-81-8
alpha-(3-(methylnitrosoamino)propyl)-3-pyridinemethanol
3-pyridinemethanol, alpha-(3-(methylnitrosoamino)propyl)-
ccris 3049
4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol
4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol
nnal
n-(4-hydroxy-4-pyridin-3-ylbutyl)-n-methylnitrous amide
C19574
unii-en7pix794w
racemic nnal
en7pix794w ,
FT-0672057
FT-0672059
FT-0672058
4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)butan-1-ol
SCHEMBL452534
CHEBI:82569
NCGC00357282-01
dtxsid8020880 ,
tox21_303708
dtxcid40880
cas-76014-81-8
.alpha.-(3-(methylnitrosoamino)propyl)-3-pyridinemethanol
3-pyridinemethanol, .alpha.-(3-(methylnitrosoamino)propyl)-
(+/-)-nnal
nnal, (+/-)-
4-[methyl(nitroso)amino]-1-(pyridin-3-yl)butan-1-ol
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, analytical standard
AKOS030242946
C90539
n-(4-hydroxy-4-(pyridin-3-yl)butyl)-n-methylnitrous amide
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (nnal)
Q27156083
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (1.0 mg/ml in methanol)
alpha-[3-(methylnitrosoamino)propyl]-3-pyridinemethanol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The cancer initiating/promoting nature of cigarette smoke can be attributed to its various constituents including nicotine, which is the major psychoactive component, and several other toxic constituents, such as nitrosamines, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, and polycyclic aromatic hydrocarbons."( Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis.
Batra, SK; Kaur, S; Kumar, S; Momi, N; Ponnusamy, MP; Wittel, UA, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
"Epidemiologic studies show a dose-response relationship between cigarettes per day and health outcomes such as heart and lung disease, and health outcomes are related to some biomarkers of tobacco exposure."( Relationships between cigarette consumption and biomarkers of tobacco toxin exposure.
Carmella, SG; Han, S; Hatsukami, DK; Hecht, SS; Joseph, AM; Le, CT; Murphy, SE; Zhang, Y, 2005
)
0.33
" The discrepancy between cotinine levels in relation to disease risk comparing active versus passive smoking suggests a nonlinear tobacco smoke dose-response and/or that cotinine is not providing an accurate measure of exposure to the toxic constituents of secondhand tobacco smoke."( Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers.
Benowitz, N; Eisner, MD; Goniewicz, ML; Havel, C; Jacob, P; Koszowski, B; Lazcano-Ponce, E; Sobczak, A; Zielinska-Danch, W, 2010
)
0.36
" The association between the NNAL-Gluc/free NNAL ratio and UC risk was significant in a dose-response manner."( Low ratio of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol-glucuronides (NNAL-Gluc)/free NNAL increases urothelial carcinoma risk.
Chung, CJ; Hsueh, YM; Lee, HL; Lin, P; Pu, YS; Shiue, HS; Su, CT; Yang, HY, 2011
)
0.37
"The dose-response between CPD and nicotine equivalents, and NNAL and PAH was flat for Black but positive for White smokers (Race × CPD interaction, all ps < ."( Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.
Benowitz, NL; Dains, KM; Dempsey, D; Jacob, P; Wilson, M, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
biomarkerA substance used as an indicator of a biological state.
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
nitrosamineN-Nitroso amines, compounds of the structure R2NNO. Compounds RNHNO are not ordinarily isolable, but they, too, are nitrosamines. The name is a contraction of N-nitrosoamine and, as such, does not require the N locant.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.33650.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (198)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (5.56)18.2507
2000's58 (29.29)29.6817
2010's114 (57.58)24.3611
2020's15 (7.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.77 (24.57)
Research Supply Index5.38 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (7.50%)5.53%
Reviews7 (3.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other178 (89.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]